Equine Adenovirus 1

Overview and Taxonomy of Equine Adenovirus 1

Equine adenovirus 1 (EAdV-1) is a significant viral pathogen within the Adenoviridae family, specifically classified under the genus Mastadenovirus. This genus encompasses a broad range of adenoviruses that infect mammalian hosts, and EAdV-1 is the prototypical and most well-characterized adenovirus affecting equids. Its taxonomic placement is grounded in both serological and molecular phylogenetics, distinguishing it as a distinct entity from other equine adenoviruses, most notably the antigenically and genetically divergent equine adenovirus 2 (EAdV-2) [1, 2]. The International Committee on Taxonomy of Viruses (ICTV) recognizes EAdV-1 as a species within the Mastadenovirus genus, a classification that is critical for understanding its biology, pathogenesis, and evolutionary relationships. From a global health perspective, while EAdV-1 is not considered a zoonotic agent with direct implications for human health as defined by the World Health Organization (WHO) or the Centers for Disease Control and Prevention (CDC), its economic impact on the equine industry is substantial, often warranting surveillance and control measures recommended by the World Organisation for Animal Health (WOAH). The virus is a primary causative agent of upper and lower respiratory tract disease in foals and young horses, and its taxonomy is a foundational element for diagnostic development, epidemiological tracking, and vaccine design.

Taxonomic Classification and Serological Differentiation

The formal classification of EAdV-1 began with its initial isolation and characterization in the mid-20th century, which established it as a distinct serotype within the Mastadenovirus genus. Early studies demonstrated that EAdV-1 possesses a unique antigenic profile, as determined by serum neutralization (SN) and hemagglutination inhibition (HI) assays. Critically, EAdV-1 is serologically unrelated to the other major equine adenovirus, EAdV-2, which was first isolated from diarrheic foal feces [1]. This distinction is not merely academic; it has profound implications for diagnostic testing and epidemiological surveillance. For instance, EAdV-1 hemagglutinates human type O, rhesus macaque, and equine red blood cells, a property that EAdV-2 lacks entirely [1]. This differential hemagglutination profile served as a key laboratory tool for early serotyping. Furthermore, extensive cross-neutralization studies have shown that EAdV-1 is unrelated to 30 human adenovirus serotypes, as well as other animal adenoviruses, confirming its host specificity and unique evolutionary lineage within the Mastadenovirus genus [1]. Biological classification is further supported by experimental infection studies, which confirmed the reproduction of clinical disease in specific-pathogen-free (SPF) foals, thereby fulfilling Koch's postulates and solidifying its role as a primary pathogen distinct from secondary or opportunistic agents [3, 2]. The virus's ability to cause disease in Arabian foals with severe combined immunodeficiency (SCID) is a hallmark of its pathogenesis, further differentiating the clinical impact from other equine respiratory viruses [3].

Molecular Phylogeny and Genetic Diversity

Advances in molecular biology have refined the taxonomic understanding of EAdV-1, moving beyond serology to detailed genomic and phylogenetic analyses. The hexon gene, which encodes the major capsid protein responsible for serotype specificity and is a primary target for host humoral immunity, is the most commonly used locus for molecular characterization and phylogenetic inference. Sequence analysis of the hexon gene has revealed that EAdV-1 is a highly conserved virus, with global isolates exhibiting remarkable genetic homogeneity. For example, phylogenetic studies based on partial hexon gene sequences from isolates in the Republic of Korea demonstrated 98.8–100% nucleotide similarity among themselves and with strains from Australia, India, and other regions [4]. This low level of genetic divergence suggests a stable viral genome with limited antigenic drift over time and across geographical boundaries. Despite this overall conservation, minor phylogenetic clustering is observed, with some isolates forming distinct clades that may reflect geographic or temporal separation. In the Korean study, three isolates clustered closely with Australian and Indian strains, while two others formed a separate branch, hinting at subtle evolutionary divergences that warrant further investigation [4]. Broader phylogenetic analyses have placed EAdV-1 within a specific clade of Mastadenoviruses that infect ungulates, and it is approximately 25% divergent at the nucleotide level from recently characterized bat adenoviruses, reinforcing its species-specific adaptation to equids [5]. The genomic organization of EAdV-1 is typical of mastadenoviruses, featuring a linear double-stranded DNA genome with inverted terminal repeats (ITRs) and a well-defined early and late gene expression cascade. This molecular architecture is directly linked to its replication strategy, which involves lytic infection of epithelial cells, particularly in the respiratory tract.

Epidemiological Profile and Clinical Relevance

Understanding the taxonomy of EAdV-1 is intrinsically linked to its epidemiological behavior and clinical significance. As a member of the Mastadenovirus genus, EAdV-1 is an obligate intracellular pathogen that primarily targets the epithelial cells of the respiratory tract, although ocular and enteric involvement can occur. The virus is globally distributed and has been detected in diverse equine populations, including performance horses, breeding stock, and foals [4, 6, 7, 8]. Its prevalence, however, is generally lower than that of other common equine respiratory viruses. Large-scale surveillance studies using molecular diagnostics, such as real-time quantitative PCR (qPCR), have consistently identified EAdV-1 as one of the least frequently detected respiratory viruses in sport horses, with prevalence rates often below 2% in nasal swabs and tracheal washes [6, 7]. For instance, a longitudinal study of Standardbred racehorses in training detected EAdV-1 in only 1.9% of tracheal wash samples, compared to much higher incidences for equine herpesvirus-2 (EHV-2) and equine rhinitis B virus (ERBV) [7]. Similarly, a cross-sectional survey of apparently healthy horses at a multi-day show in the United States identified EAdV-1 in a very small percentage of individuals using a nanoscale real-time PCR panel, indicating that subclinical carriage is possible but not ubiquitous [8].

The clinical disease associated with EAdV-1 varies markedly with the age and immune status of the host. In immunocompetent adult horses, infection is often subclinical or results in mild, self-limiting upper respiratory tract disease characterized by fever, serous nasal discharge, and occasional conjunctivitis [6, 3, 2]. However, in neonatal and young foals, particularly those deprived of colostrum or with concurrent immunodeficiency, EAdV-1 can cause severe, sometimes fatal, bronchopneumonia and interstitial pneumonia [3, 2]. Experimental infections in colostrum-deprived, SPF foals have demonstrated that the virus induces robust pathology, including conjunctivitis, rhinitis, tracheitis, and extensive bronchopneumonia with characteristic intranuclear inclusion bodies in epithelial cells [2]. The presence of maternal antibodies can significantly attenuate the severity of disease, highlighting the protective role of passive immunity [2]. Furthermore, Arabian foals with inherited SCID are exquisitely susceptible to severe, progressive adenoviral pneumonia, underscoring a unique host-pathogen interaction that defines a critical vulnerable population [3]. In the broader context of equine respiratory health, EAdV-1 is often detected in co-infections with other pathogens, although its role as a primary cause of disease in performance horses is considered minor compared to equine herpesviruses or equine influenza virus [6, 7]. Nevertheless, its detection in both diseased and apparently healthy horses, coupled with its ability to cause significant morbidity in young or immunocompromised animals, ensures its continued relevance in equine medicine and virology.

Viral Structure and Genomic Organization

Equine adenovirus 1 (EAdV-1) is a non-enveloped, double-stranded DNA virus belonging to the genus Mastadenovirus within the family Adenoviridae. Its structural and genomic architecture is foundational to understanding its pathogenesis, host tropism, and the molecular basis for diagnostic detection, including PCR-based surveillance and phylogenetic characterization. The virus exhibits the characteristic icosahedral symmetry typical of adenoviruses, with a capsid diameter of approximately 70–90 nm, composed of 252 capsomers arranged in a pseudo-T=25 lattice. The capsid is devoid of a lipid envelope, rendering EAdV-1 relatively resistant to environmental degradation and lipid-dissolving disinfectants, a feature that influences its transmission dynamics in equine populations, particularly within densely stabled training facilities and during multi-day equestrian events [6, 7, 8].

The major capsid protein, the hexon, is the most abundant structural polypeptide and serves as the primary target for serotype-specific neutralizing antibodies. The hexon gene is highly conserved among adenoviruses but contains hypervariable regions (HVRs) that confer serotypic and strain-specific antigenic diversity. In EAdV-1, the hexon gene has been extensively utilized for molecular detection and phylogenetic analysis, as demonstrated by Lee et al. (2022), who employed a hexon-specific PCR to detect EAdV-1 in nasal swabs from horses in the Republic of Korea. Their sequencing and phylogenetic analyses revealed that Korean isolates shared 98.8–100% nucleotide identity with each other and with foreign strains from Australia and India [4]. This level of conservation in the hexon gene suggests that while EAdV-1 is genetically stable across geographic regions, minor nucleotide polymorphisms may still differentiate strains, as indicated by the clustering of two Korean isolates as separate phylogenetic lineages [4]. The hexon’s structural integrity is critical for virion stability; it forms the capsid’s triangular facets and houses the loops that mediate interactions with the cellular coxsackievirus and adenovirus receptor (CAR) and integrins, albeit the specific receptor usage for EAdV-1 in equine epithelial cells remains to be fully elucidated.

The penton base protein, located at each of the 12 vertices of the icosahedron, anchors the fiber protein, which projects outward from the capsid surface. The fiber is a homotrimeric protein responsible for primary attachment to host cell receptors. In human adenoviruses, the fiber’s knob domain binds to CAR, but for EAdV-1, the precise receptor binding mechanism is less well defined. The fiber length and the presence of a shaft domain with pseudorepeat motifs influence viral tropism. Notably, the fiber protein of EAdV-1 is antigenically distinct from that of equine adenovirus 2 (EAdV-2), as demonstrated by cross-hemagglutination and serum neutralization assays. Studdert and Blackney (1982) reported that EAdV-1 hemagglutinates human O, rhesus macaque, and equine red blood cells, whereas EAdV-2 does not, indicating that the fiber’s hemagglutinin domain is a major determinant of serotypic differentiation [1]. This hemagglutination property is exploited in diagnostic serology, but the structural basis for the differential binding, likely residing in the fiber knob’s conformation, remains a subject of virological inquiry.

The genomic organization of EAdV-1 is typical of mastadenoviruses, comprising a linear, double-stranded DNA genome of approximately 36–38 kilobase pairs. Flanking the genome are inverted terminal repeats (ITRs) that are essential for replication initiation. The genome is functionally divided into early (E1–E4) and late (L1–L5) transcription units, which are temporally regulated during the lytic cycle. The early region E1A is the first to be expressed and encodes proteins that transactivate other viral promoters and manipulate the host cell cycle to promote viral replication. The E1B region encodes proteins that inhibit apoptosis, a conserved strategy among adenoviruses to prolong host cell survival during viral replication. The DNA polymerase gene, often targeted in degenerate PCR assays for pan-adenovirus detection, exhibits approximately 25% nucleotide divergence between EAdV-1 and bat adenoviruses, as documented by Lima et al. (2013) in their study of a Brazilian vampire bat adenovirus [5]. This level of divergence underscores the species specificity within the Mastadenovirus genus and validates the use of conserved polymerase motifs (e.g., the A, B, and C families) for broad-spectrum adenovirus discovery.

The late region is transcribed after the onset of DNA replication and encodes the structural capsid proteins, including hexon, penton base, fiber, as well as core proteins (e.g., proteins V, VII, μ) that compact the viral DNA within the capsid. Protein VII, a highly basic arginine-rich core protein, associates with the viral DNA and facilitates its delivery into the host nucleus upon uncoating. The viral protease, encoded by the L3 region, processes precursor capsid proteins to their mature forms, a step required for the production of infectious progeny virions. Assembly of the virion occurs in the host cell nucleus, where the capsid is formed around the newly replicated genome, and the virus is released upon cell lysis.

The structural stability conferred by the non-enveloped capsid is a double-edged sword: it allows EAdV-1 to persist on fomites and in the environment, contributing to transmission in equine facilities, but it also makes the virus susceptible to direct-acting disinfectants such as bleach and aldehydes, though not to lipid solvents. From a regulatory perspective, the World Organisation for Animal Health (WOAH) does not list EAdV-1 as a notifiable pathogen, but its detection in respiratory panels is increasingly recognized as relevant to equine respiratory disease complex, particularly in young horses and those under intensive training [6, 7, 2]. The structural details of the hexon hypervariable loops, in particular, underpin the serotype-specific immunity that distinguishes EAdV-1 from EAdV-2 [1], a distinction that is critical for the development of diagnostic assays and future vaccine strategies. The genomic architecture of EAdV-1, with its conserved hexon and polymerase sequences, continues to provide the molecular scaffolding for epidemiological surveillance and for understanding the virus’s evolution within the equine host.

Molecular Pathogenesis and Virulence Factors

The pathogenic trajectory of Equine Adenovirus 1 (EAdV-1) is a complex interplay of viral cytopathology, host immune competence, and the specific microenvironment of the equine respiratory tract. As a member of the genus Mastadenovirus, EAdV-1 employs a sophisticated molecular arsenal to establish infection, subvert host defenses, and induce a spectrum of clinical outcomes ranging from subclinical shedding to fatal pneumonia. The molecular pathogenesis of EAdV-1 must be understood not as a monolithic process, but as a dynamic equilibrium influenced profoundly by the age, immunological status, and genetic predisposition of the equine host.

Viral Attachment, Entry, and Cellular Tropism

The initial step in EAdV-1 pathogenesis is the attachment of the virus to susceptible host cells. The primary determinant of this interaction is the viral hexon protein, a major capsid component that dictates serotype specificity and host range. Phylogenetic analyses of the hexon gene from global isolates, including those from the Republic of Korea, reveal a high degree of sequence conservation (98.8–100% similarity), suggesting that this critical viral attachment protein is under strong selective pressure to maintain its structure for efficient binding to equine-specific cellular receptors [4]. The fiber protein, another key structural component responsible for high-affinity binding to the coxsackievirus and adenovirus receptor (CAR) or sialic acid residues, dictates the breadth of tissue tropism. EAdV-1 demonstrates a pronounced tropism for epithelial cells of the respiratory tract, conjunctiva, and, in severe cases, the intestinal tract and liver [3, 2]. This tropism is reflected by the clinical signs of rhinitis, tracheitis, bronchitis, and conjunctivitis observed in experimental infections [2]. The virus has been isolated from and detected via PCR in both nasopharyngeal swabs and tracheal washes, confirming its preferential replication within the ciliated and non-ciliated epithelial cells lining the conducting airways [7, 8].

Following attachment, the virus is internalized via receptor-mediated endocytosis. The subsequent escape from the endosome and disassembly of the capsid are orchestrated by the viral penton base protein, which interacts with cellular integrins (e.g., αvβ3 and αvβ5) to trigger membrane disruption. This process delivers the viral DNA genome to the nucleus, where transcription and replication occur. The efficiency of this entry process is underscored by the rapid onset of clinical disease observed in experimental settings; specific-pathogen-free foals developed clinical signs and pathological lesions within six days of inoculation [2].

Replication, Cytopathology, and Intranuclear Inclusion Body Formation

The hallmark of adenoviral replication in permissive cells is the formation of large, basophilic or amphophilic intranuclear inclusion bodies. These structures represent paracrystalline arrays of newly assembled virions within the host cell nucleus, and their presence is a pathognomonic feature of EAdV-1 infection in histological sections [3]. The replication cycle is profoundly cytocidal, leading to cellular swelling (cytomegaly), nuclear degeneration, and eventual lysis of the infected epithelial cell. This lytic destruction of the respiratory epithelium is the primary driver of the observed clinical pathology.

In the experimental transmission study by McChesney et al. (1974), the pathological lesions in infected foals were characterized by hyperplasia, swelling, and necrosis of bronchiolar and alveolar epithelial cells, directly attributable to viral replication [3]. The loss of the mucociliary escalator, a critical innate defense mechanism, results in the accumulation of cellular debris, mucus, and inflammatory exudate within the airways, leading to the clinical signs of nasal discharge, cough, and dyspnea. The severity of this cytopathic effect is directly correlated with the viral load. Quantitative PCR studies have demonstrated that EAdV-1 genome detection in tracheal washes is a more sensitive indicator of active lower airway infection than detection in nasopharyngeal swabs, suggesting that the virus can establish a more productive infection within the bronchial and bronchiolar epithelium [7].

Immune Evasion and the Role of Immunosuppression

A defining feature of EAdV-1 pathogenesis is its intricate relationship with the host immune system, particularly the interplay between viral virulence and host immunodeficiency. While EAdV-1 can cause self-limiting respiratory disease in immunocompetent foals, it is capable of inducing fulminant, fatal pneumonia in immunocompromised individuals. The most striking example of this is observed in Arabian foals affected by Severe Combined Immunodeficiency (SCID), a primary immunodeficiency characterized by an absence of functional B and T lymphocytes.

The landmark study by McChesney et al. (1974) provided critical experimental evidence for this phenomenon. Among the experimental foals, one Arabian sibling exhibited severe, absolute lymphopenia prior to EAdV-1 exposure. This lymphopenic foal succumbed to a rapidly progressive pneumonia within seven days of inoculation. Postmortem examination revealed a "paucity of lymphocytes in the spleen, lymph nodes, Peyer's patches, and thymus" , a hallmark of SCID, along with severe viral pneumonia [3]. In contrast, the other two Arabian siblings, who did not have pre-existing lymphopenia, developed clinical signs and pathological changes similar to those of non-Arabian experimental foals [3]. This experiment elegantly demonstrates that the virus’s pathogenic potential is significantly amplified in the absence of an adaptive immune response. The virus is not inherently more cytolytic in these animals; rather, the host’s inability to mount a cytotoxic T-lymphocyte (CTL) response or produce neutralizing antibodies allows unrestricted viral replication.

EAdV-1 also possesses intrinsic mechanisms to modulate the host immune response. Like other adenoviruses, EAdV-1 likely encodes early region (E1, E3) proteins that interfere with interferon signaling, antigen presentation via major histocompatibility complex (MHC) class I downregulation, and the induction of apoptosis. These molecular countermeasures allow the virus to delay and blunt the immune response, facilitating a longer replication phase and increasing the likelihood of transmission. The inactivated EAdV-1 vaccine study by Tizard and Studdert (1982) provides indirect evidence for the importance of cell-mediated immunity. Vaccinated horses developed a robust in vitro lymphocyte blastogenesis response specific to EAdV-1 antigen, with stimulation indices reaching 18.6, far exceeding the background responses of control horses [9]. This suggests that the cellular arm of the immune system is critically engaged during infection and that effective immunity requires more than just virus-neutralizing (VN) antibodies.

Pathogenesis of Disseminated Disease and Abortion

While respiratory disease is the most common manifestation of EAdV-1, the virus can disseminate hematogenously to cause systemic infection. The experimental infections by McChesney et al. (1974) included the intrauterine inoculation of fetuses, which resulted in fetal death and abortion [3]. This establishes that EAdV-1 has the capacity to cross the placenta and replicate in fetal tissues, leading to placentitis and fetal demise. The pathogenesis of abortion likely involves viral replication in the fetal trophoblast and endothelial cells of the placental microvasculature, leading to thrombosis, infarction, and subsequent fetal death. This pathway is analogous to other abortigenic equine viruses, such as Equine Herpesvirus-1 (EHV-1) [10], and highlights the potential for EAdV-1 to cause significant reproductive loss, although it appears to be a less common cause of abortion compared to EHV-1.

Co-infection and Synergistic Pathogenesis

In the natural environment, EAdV-1 rarely acts as a sole pathogen. Field studies employing multiplex qPCR panels have demonstrated that EAdV-1 is frequently detected in the context of polymicrobial infections. Doubli-Bounoua et al. (2016) found that up to four different viruses could be detected simultaneously in the airways of racehorses, although EAdV-1 was among the least common [7]. The clinical significance of these co-infections is a subject of active investigation. It is hypothesized that EAdV-1 infection, by compromising the integrity of the respiratory epithelium and modulating local immunity, can predispose the host to secondary bacterial or viral infections. For instance, the disruption of the mucosal barrier could facilitate the invasion of opportunistic bacteria like Streptococcus equi subsp. zooepidemicus, a common isolate from equine respiratory samples [8]. This synergistic pathogenesis likely exacerbates the severity of the clinical disease.

Genetic Diversity and Strain Variation

The molecular epidemiology of EAdV-1 reveals a relatively low level of genetic diversity within the hexon gene. A study of Korean isolates found that they shared 98.8–100% nucleotide identity with each other and with strains from Australia and India, indicating a high degree of global conservation of this immunodominant antigen [4]. This conservation is promising for vaccine development, as a single vaccine candidate might be broadly protective against geographically diverse strains. However, the existence of a second serotype, Equine Adenovirus 2 (EAdV-2), isolated from foal feces and antigenically distinct from EAdV-1 [1], introduces another layer of complexity. EAdV-2 does not hemagglutinate equine or human erythrocytes and is serologically unrelated to EAdV-1 by serum neutralization [1]. This suggests that the two viruses utilize different receptors and may have distinct tissue tropisms, with EAdV-2 being more associated with the gastrointestinal tract. The molecular basis for the difference in hemagglutination and receptor usage between these two serotypes likely resides in the fiber knob domain, a region of the viral genome that undergoes significant sequence divergence.

The ability of EAdV-1 to persist in populations of apparently healthy horses is a key aspect of its pathogenesis. Stout et al. (2020) detected EAdV-1 DNA in feces from apparently healthy horses at a multi-day show, indicating that subclinical shedding occurs and serves as a reservoir for new infections [8]. This subclinical carrier state likely represents a dynamic balance between low-level viral replication and host immune control. Stressors such as transportation, weaning, training, or concurrent illness can disrupt this equilibrium, leading to viral reactivation and clinical disease. This pattern is reminiscent of the latency-reactivation cycle of EHV-1 and EHV-2 [6, 10]. The molecular mechanisms governing the establishment and maintenance of this persistent state in EAdV-1 remain poorly defined but likely involve the integration of the viral genome into a latent state or the existence of a cell type that supports non-cytolytic, low-grade replication.

Epidemiology and Genetic Diversity

Equine adenovirus 1 (EAdV-1) occupies a unique niche within the equine respiratory virome, characterized by a global distribution yet a paradoxical pattern of sporadic clinical significance. Unlike the ubiquitous and frequently pathogenic equine herpesviruses (EHV-1, EHV-4, EHV-2, EHV-5) or the epizootic potential of equine influenza virus, EAdV-1 is consistently identified as one of the least common respiratory viruses detected in equine populations worldwide [6, 7]. This low prevalence, however, belies a complex epidemiological picture shaped by host factors, environmental stressors, and a genetic diversity that suggests ongoing viral evolution and adaptation. Understanding the true burden of EAdV-1 requires a nuanced examination of its prevalence across different geographies, management systems, and age cohorts, coupled with a molecular dissection of its genomic variability.

Global Prevalence and Geographic Distribution

The prevalence of EAdV-1, as determined by molecular detection methods, varies considerably across studies, reflecting differences in diagnostic techniques, sampled populations, and geographic regions. A seminal study from the Republic of Korea, employing a hexon-specific PCR on nasal swabs from 359 horses at Korea Racing Authority facilities, reported a prevalence of just 1.4% (5/359) [4]. This figure aligns with findings from longitudinal surveillance of racehorses in France, where the monthly incidence of EAdV-1 detection in tracheal washes was 1.9% [7]. Similarly, a comprehensive survey of apparently healthy horses at a multi-day show in the United States, using a nanoscale real-time PCR panel, detected EAdV-1 in a small proportion of fecal samples, further underscoring its presence even in subclinical carriers [8]. These data collectively position EAdV-1 as a relatively infrequent finding compared to other respiratory pathogens. For context, the same French study reported monthly incidences of 27.9% for EHV-5 and 24.8% for EHV-2 in tracheal washes [7], highlighting the numerical dominance of gammaherpesviruses in the equine airway.

The geographic range of EAdV-1 is truly global. The Korean isolates demonstrated high genetic similarity (98.8–100% nucleotide identity) to strains from Australia and India [4], suggesting a widespread dissemination that likely mirrors the international movement of horses for competition, breeding, and sale. This global distribution is a critical factor for disease management, as it implies that no equine population is truly naïve to the virus. The World Organisation for Animal Health (WOAH) recognizes the importance of surveillance for equine respiratory pathogens, and the detection of EAdV-1 across diverse continents, from Asia to Europe to North America, reinforces its status as a ubiquitous, albeit low-prevalence, agent.

Risk Factors and Host Susceptibility

Identifying risk factors for EAdV-1 infection has proven challenging due to its low overall prevalence. The Korean study, which analyzed sex, age, region, breed, and activity, found no statistically significant associations with PCR positivity [4]. This lack of clear demographic risk factors contrasts sharply with other equine viruses; for instance, EHV-1 myeloencephalopathy (EHM) shows a strong association with age (>9 years) and male sex [11]. The absence of such clear-cut risk factors for EAdV-1 suggests that infection is more stochastic or is driven by factors not captured in standard epidemiological surveys, such as transient immunosuppression or specific environmental exposures.

The most profound risk factor for severe EAdV-1 disease is a compromised immune system, particularly in the context of combined immunodeficiency (CID) in Arabian foals. Early experimental transmission studies demonstrated that Arabian foals with pre-existing severe lymphopenia developed rapidly progressive pneumonia and died following EAdV-1 exposure, whereas non-lymphopenic siblings and non-Arabian foals developed milder, self-limiting respiratory disease [3]. This finding is biologically pivotal. It establishes that while EAdV-1 can infect immunocompetent horses, it is the host's immune status, specifically the absence of functional T and B lymphocytes, that dictates the transition from a subclinical or mild infection to a fatal, disseminated disease. This mechanism is analogous to the severe adenoviral disease seen in human patients with primary immunodeficiencies or those undergoing hematopoietic stem cell transplantation, a parallel that underscores the fundamental biology of adenoviruses as opportunistic pathogens.

Age is another critical, albeit nuanced, risk factor. Neonatal foals, particularly those deprived of colostrum, are highly susceptible to severe respiratory disease and pneumonia following experimental EAdV-1 infection [3, 2]. Colostrum-deprived foals developed severe clinical signs, including conjunctivitis, rhinitis, and bronchopneumonia, while colostrum-fed foals showed attenuated disease, presumably due to passive transfer of maternal neutralizing antibodies [2]. Older foals (2–4 months of age) were less severely affected than neonates [3], suggesting that age-related maturation of the immune system confers increasing resistance. This age-dependent susceptibility is a hallmark of many respiratory viral infections in horses, including EHV-1 and equine influenza, where young animals are at highest risk for primary infection and clinical disease.

Genetic Diversity and Molecular Epidemiology

The genetic diversity of EAdV-1, while not as extensive as that seen in RNA viruses like equine influenza, is demonstrable and carries implications for viral fitness, antigenicity, and diagnostics. The most comprehensive molecular epidemiological data come from the Korean study, which sequenced partial hexon genes from five positive isolates. Phylogenetic analysis revealed that these Korean isolates shared 98.8–100% nucleotide similarity with each other and with foreign strains from Australia and India [4]. However, a critical finding was that two of the five Korean isolates formed a separate phylogenetic cluster, distinct from the other three [4]. This clustering indicates the co-circulation of multiple genetic lineages within a single, relatively confined geographic area (Korea Racing Authority facilities). This phenomenon suggests that EAdV-1 is not a static, monotypic virus but is undergoing continuous, albeit slow, genetic drift.

The hexon gene, which encodes the major capsid protein, is a primary target for neutralizing antibodies and is thus under selective pressure from the host immune system. The observed genetic variation in the hexon gene, even if minor (1.2% divergence), could theoretically alter antigenic epitopes, potentially allowing viral variants to escape pre-existing immunity. This is a well-documented mechanism for other adenoviruses, such as human adenovirus serotypes, where genetic variation in the hexon hypervariable regions drives serotype diversity and necessitates periodic updates to diagnostic assays. For EAdV-1, the practical implication is that PCR-based diagnostic assays targeting conserved regions of the hexon gene are likely to remain robust, but serological assays based on a single reference strain may underestimate the true prevalence of infection if antigenically divergent strains are circulating.

The relationship between EAdV-1 and the second equine adenovirus serotype, EAdV-2, is also a key aspect of genetic and antigenic diversity. EAdV-2 was first isolated from the feces of diarrheic foals and was shown to be antigenically distinct from EAdV-1 by serum neutralization and hemagglutination inhibition assays [1]. Critically, EAdV-2 does not hemagglutinate human, rhesus macaque, or equine red blood cells, a property that distinguishes it from EAdV-1 [1]. This antigenic distinction is fundamental: it means that infection with one serotype does not confer cross-protective immunity against the other. The seroprevalence of neutralizing antibodies to EAdV-2 was found to be 77% in a survey of 339 equine serum samples [1], indicating that EAdV-2 is far more prevalent than EAdV-1. This high seroprevalence suggests that EAdV-2 is an endemic, widely circulating virus that likely causes frequent, subclinical infections. The existence of two distinct serotypes with different tissue tropisms (respiratory vs. enteric) and vastly different prevalence rates highlights the complexity of the equine adenovirus landscape. Future molecular epidemiological studies must distinguish between these two serotypes to accurately assess the disease burden attributable to each.

Transmission Dynamics and Environmental Persistence

The transmission of EAdV-1 is primarily horizontal, via the respiratory route, through direct contact with infected horses or inhalation of aerosolized virus from nasal secretions. The detection of EAdV-1 in nasal swabs from both clinically affected and apparently healthy horses [4, 8] confirms that subclinical shedders are a key reservoir for maintaining viral circulation within a population. The duration of shedding is not well-defined for EAdV-1, but for other equine adenoviruses and mastadenoviruses in general, shedding can persist for weeks to months following primary infection, particularly in immunocompromised hosts.

Transportation and commingling of horses are well-established risk factors for the spread of equine infectious diseases. Transportation stress can temporarily suppress immune function, increasing the risk of both primary viral infection and reactivation of latent viruses [6]. While EAdV-1 is not known to establish latency in the same manner as EHV-1, the stress of transport could increase susceptibility to primary infection or prolong the period of viral shedding. The international movement of horses for competition, as seen in the EHV-1 outbreak during a show-jumping competition in Valencia [11], creates a perfect storm for the dissemination of respiratory pathogens. Although EAdV-1 was not the agent in that outbreak, the same principles apply: high-density housing, mixing of horses from diverse geographic origins, and physiological stress facilitate viral transmission.

Environmental persistence is a critical, yet understudied, aspect of EAdV-1 epidemiology. Adenoviruses are generally considered to be relatively stable in the environment, being non-enveloped viruses that are resistant to many common disinfectants and desiccation. This environmental stability means that fomites, including shared water buckets, feed tubs, grooming equipment, and even the hands of handlers, could serve as vehicles for indirect transmission. The detection of EAdV-1 in fecal samples from healthy horses [8] raises the possibility of fecal-oral transmission, although this is likely a minor route compared to respiratory aerosolization. The practical implication for biosecurity is that rigorous cleaning and disinfection protocols, using agents effective against non-enveloped viruses (e.g., accelerated hydrogen peroxide, bleach solutions), are essential to break the chain of transmission in barns and veterinary hospitals.

Co-infection and Clinical Context

EAdV-1 rarely acts alone. In the Korean study, none of the five EAdV-1-positive horses had detectable co-infections with equine influenza virus, EHV-1/4, or Streptococcus equi [4]. However, this may reflect the specific pathogens tested rather than a true absence of co-infection. In the French longitudinal study, up to four different viruses were detected concomitantly in the same horse, and EAdV-1 was detected alongside EHV-2, EHV-5, and equine rhinitis B virus [7]. This high rate of co-infection is the rule rather than the exception in equine respiratory disease, making it difficult to attribute clinical signs solely to EAdV-1.

The clinical significance of EAdV-1 detection must be interpreted with caution. In the French study, detection of viral genome in nasopharyngeal swabs was not associated with any clinical sign [7]. However, coughing was significantly associated with detection of EHV-2 and ERBV in tracheal washes [7]. This suggests that EAdV-1, when detected in the upper airways (nasal swabs), may often be an incidental finding or a bystander virus that is not the primary driver of disease. The true pathogenic potential of EAdV-1 is most clearly realized in the context of immunodeficiency, where it can cause a fulminant, fatal pneumonia [3]. In immunocompetent horses, EAdV-1 infection is likely a mild, self-limiting upper respiratory tract infection that may contribute to the complex, multifactorial etiology of inflammatory airway disease (IAD) but is rarely the sole cause. This nuanced understanding is critical for clinicians: a positive PCR result for EAdV-1 should not automatically be interpreted as the cause of clinical signs, especially in the presence of other, more pathogenic agents.

Clinical Manifestations and Impact on Performance

The Spectrum of Clinical Disease in Equine Adenovirus 1 Infection

Equine adenovirus 1 (EAdV-1) is a ubiquitous pathogen of Equidae, yet its clinical expression is profoundly modulated by host age, immunological competence, and the presence of concurrent infections. The virus is primarily associated with respiratory tract disease, but its clinical manifestations range from completely inapparent infections to severe, life-threatening pneumoenteric syndromes, particularly in immunocompromised neonates. Understanding this spectrum is critical for the practicing veterinarian, as the detection of EAdV-1 in a horse, especially a mature athlete, does not automatically imply causality of any observed clinical signs [6, 7, 8].

Respiratory Tract Disease and Conjunctivitis

The most frequently documented clinical presentation of EAdV-1 infection in immunocompetent foals and weanlings is an acute, febrile upper respiratory tract infection. Classic experimental challenge studies in specific-pathogen-free (SPF) foals have definitively demonstrated the virus’s capacity to induce overt disease. Cesarean-derived, colostrum-deprived foals inoculated with EAdV developed clinical evidence of conjunctivitis, serous to mucopurulent nasal discharge, and明显的 upper respiratory tract pathology within days of exposure [2]. These signs progress to include a deep, productive cough and dyspnea in more severe cases [3]. The ocular component, conjunctivitis with chemosis and epiphora, is a hallmark that helps differentiate EAdV-1 from some other respiratory viral pathogens in young stock, although it is not pathognomonic.

In a landmark experimental transmission study involving Arabian and non-Arabian foals, the clinical syndrome was clearly defined: fever (often exceeding 39.5°C), bilateral nasal discharge (initially serous, later mucopurulent), and labored breathing were consistently observed in neonates [3]. Importantly, this study highlighted that colostrum-fed foals developed significantly milder disease than colostrum-deprived cohorts, underscoring the protective role of maternally-derived antibodies. Similarly, in the SPF foal model, the presence of passive immunity (from a 12-hour suckling window) markedly attenuated the clinical severity, reducing the extent of pneumonia and the degree of dyspnea at necropsy [2].

Severe Disease and the Immunocompromised Host: The Arabian Foal Phenotype

The most devastating clinical manifestations of EAdV-1 are reserved for foals with underlying immunodeficiency, most notably the severe combined immunodeficiency (SCID) syndrome seen in Arabian foals. While the earliest experimental work demonstrated that normal Arabian foals responded similarly to non-Arabian foals, a critical subset of Arabian foals, those with pre-existing severe absolute lymphopenia, developed a fulminant, fatal disease [3]. These lymphopenic foals exhibited a rapid progression of pneumonia, and at necropsy, a striking paucity of lymphocytes in all lymphoid organs (spleen, lymph nodes, Peyer’s patches, and thymus) was observed alongside a progressing, severe interstitial pneumonia [3]. This pattern is consistent with an inability to mount an adaptive immune response, allowing unchecked viral replication and diffuse pulmonary damage.

In these immunocompromised animals, the clinical picture is not simply a more severe version of the respiratory syndrome; it often includes systemic signs such as profound lethargy, anorexia, and rapid weight loss. The pneumonia is characteristically bronchointerstitial, progressing to diffuse alveolar damage. The pathological hallmark, both in natural and experimental cases, is the presence of basophilic intranuclear inclusion bodies within hyperplastic, swollen, and necrotic epithelial cells of the bronchioles and alveoli [3]. This finding, while diagnostic, is rarely obtainable in the live horse and underscores the need for molecular diagnostics (PCR) on nasopharyngeal or tracheal samples for confirmation [7].

Subclinical Infection and the Carrier State in Mature Horses

In stark contrast to the dramatic disease seen in neonates, EAdV-1 infection in mature, immunocompetent horses is most frequently subclinical. This is a critical point for the equine practitioner, particularly when investigating poor performance or inflammatory airway disease (IAD) in athletic horses. Multiple large-scale epidemiological surveys have now demonstrated that EAdV-1 is detected at a very low prevalence in both healthy and clinically ill adult populations. In a study of 359 horses at training facilities in the Republic of Korea, only 1.4% (5/359) tested positive for EAdV-1 by PCR on nasal swabs, and of those five, only a single horse exhibited any clinical respiratory signs [4]. This pattern of detection without disease is further supported by work from a multi-day horse show in the United States, where EAdV-1 was identified via a sensitive nanoscale real-time PCR panel in the feces of apparently healthy horses [8]. The presence of viral nucleic acid in fecal samples raises intriguing questions about possible enteric shedding or a transient viremia with gastrointestinal involvement, though the clinical significance of this finding in healthy adults remains undefined.

A particularly informative longitudinal study on 52 Standardbred racehorses in training provided robust data on the clinical relevance of EAdV-1 detection in the airway. Over 27 consecutive months, tracheal washes (TW) and nasopharyngeal swabs (NS) were collected monthly and tested for a comprehensive panel of respiratory viruses, including EAdV-1 [7]. The monthly incidence of EAdV-1 detection in TW was only 1.9%. Critically, the statistical analysis revealed that detection of EAdV-1 genome, in either NS or TW, was not associated with any clinical sign, including nasal discharge, coughing, or an increased tracheal mucus score [7]. This finding is of paramount importance when interpreting diagnostic results. The detection of EAdV-1 in a mature horse with poor performance should not be assumed to be causative. The study explicitly showed that coughing was significantly associated with EHV-2 and equine rhinitis B virus (ERBV) detection in TW, but not with EAdV-1 [7].

Impact on Athletic Performance: A Cautious Assessment

The direct impact of EAdV-1 infection on equine athletic performance is a topic of considerable clinical interest but one for which the evidence is surprisingly thin. In a comprehensive narrative review of respiratory viruses affecting performing horses, the authors concluded that while acute respiratory viral infections can lead to a reduced ability to perform, the direct association between EAdV-1 and performance decrement is "unclear in subclinically affected horses" [6]. This statement encapsulates the current dilemma. In the acute phase of disease, particularly in a naive weanling or yearling, the fever, malaise, and respiratory compromise will obviously preclude training or competition. The metabolic demands of a febrile illness, coupled with reduced feed intake and potential hypoxemia from pneumonia, would necessitate a prolonged period of rest.

However, the more common scenario in the adult performance horse is the detection of EAdV-1 during routine health screening or as part of a diagnostic workup for IAD or poor performance, without overt clinical illness. In such cases, the virus is likely acting as a bystander or is present at levels below a pathogenic threshold. The data from the Standardbred cohort study strongly support this view, as EAdV-1 detection in the airway was not linked to any of the cardinal signs of IAD (cough, excess mucus, increased tracheal neutrophils) [7]. Therefore, attributing a lack of performance to EAdV-1 in a subclinically infected horse is likely erroneous and could lead to missed diagnoses of more significant underlying issues such as dynamic airway collapse, lower airway inflammation from non-infectious causes, or musculoskeletal pain.

Nevertheless, one cannot entirely dismiss a potential role for EAdV-1 in the complex, multifactorial syndrome of poor performance. Viral infections, even subclinical ones, can trigger or exacerbate airway inflammation through the release of cytokines and the recruitment of inflammatory cells. While the data do not show a direct link to IAD for EAdV-1, it must be considered that the studies have not been powered to detect very subtle decrements in performance. Furthermore, co-infections are common in the equine respiratory tract. In the Korean study, all five EAdV-1 positive horses were negative for equine influenza, EHV-1/4, and Streptococcus equi [4]; however, other studies have documented the detection of up to four different viruses concurrently in the same animal [7]. The synergistic impact of a polymicrobial infection involving EAdV-1 on performance remains largely unstudied. The World Organisation for Animal Health (WOAH) recognizes the importance of respiratory viruses in the international movement of horses, and while EAdV-1 is not listed as a notifiable disease, its potential to contribute to respiratory morbidity in young horses warrants continued surveillance, particularly in training yards.

In summary, the clinical impact of EAdV-1 is heavily dependent on the host. It is a significant pathogen for neonatal foals, particularly those with compromised immune systems, causing a characteristic febrile respiratory syndrome with conjunctivitis that can progress to fatal pneumonia. In contrast, in the mature equine athlete, EAdV-1 is predominantly an incidental finding with weak to no association with clinical disease or measurable performance loss [6, 7]. The veterinarian must exercise diagnostic restraint and rely on a complete clinical picture, including cytology from tracheal washes and ruling out more established causes of IAD, before implicating EAdV-1 in a case of poor performance.

Diagnostic Approaches and Molecular Detection

The accurate and timely diagnosis of Equine Adenovirus 1 (EAdV-1) infection is a cornerstone of effective equine respiratory disease management, epidemiological surveillance, and the implementation of appropriate biosecurity measures. The diagnostic landscape for EAdV-1 has evolved significantly from traditional virus isolation and serological methods to a predominance of highly sensitive and specific molecular techniques. This shift reflects a broader trend in veterinary virology, where the need for rapid, high-throughput, and discriminatory detection methods is paramount, particularly in the context of managing respiratory disease in athletic and valuable equine populations. The following sections provide an exhaustive analysis of the current diagnostic approaches, with a primary focus on molecular detection, its applications, limitations, and the critical context in which these tools are deployed.

Historical and Conventional Diagnostic Methods

Prior to the widespread adoption of molecular diagnostics, the identification of EAdV-1 relied on a combination of virus isolation, serology, and histopathology. Virus isolation, typically performed in equine fetal kidney (EFK) or other susceptible cell lines, was considered the gold standard. This approach, while definitive, is labor-intensive, time-consuming (often requiring several days to weeks for cytopathic effect to develop), and requires specialized laboratory infrastructure and expertise. The sensitivity of virus isolation is also variable, heavily dependent on the quality of the sample, the stage of infection, and the presence of neutralizing antibodies in the sample. Historically, experimental infections in foals demonstrated that EAdV could be reliably isolated from infected tissues and secretions, confirming its etiological role in respiratory disease [3, 2]. However, for routine clinical diagnostics and large-scale surveillance, these methods are impractical.

Serological assays, such as virus neutralization (VN) tests and hemagglutination inhibition (HI) tests, have been used to detect antibodies against EAdV-1. The VN test, which measures the ability of serum antibodies to neutralize viral infectivity, is highly specific and can differentiate between EAdV-1 and the antigenically distinct EAdV-2, as the two serotypes show no cross-neutralization [1]. The HI test exploits the ability of EAdV-1 to agglutinate red blood cells, a property notably absent in EAdV-2 [1]. While serology is valuable for seroprevalence studies and assessing population-level immunity, it has significant limitations for diagnosing active infection. A positive serological result can indicate past exposure or vaccination, and a four-fold rise in antibody titers between acute and convalescent sera is required to confirm recent infection, a timeline that is clinically irrelevant for acute disease management. Furthermore, the presence of maternally derived antibodies in young foals can confound serological interpretation [2]. Histopathological examination of tissues, particularly from fatal cases, can reveal characteristic intranuclear inclusion bodies in epithelial cells of the respiratory tract, along with hyperplasia, swelling, and necrosis [3]. While pathognomonic, this method is only applicable post-mortem and is not a tool for ante-mortem diagnosis.

The Primacy of Molecular Detection: Polymerase Chain Reaction (PCR)

The advent of polymerase chain reaction (PCR) technology has revolutionized the diagnosis of EAdV-1, establishing it as the preferred and most powerful diagnostic modality. Molecular diagnostics, particularly real-time quantitative PCR (qPCR), offer unparalleled sensitivity, specificity, and speed, enabling the detection of minute quantities of viral DNA directly from clinical specimens. This has facilitated a shift from diagnosing clinical disease to detecting subclinical infections and understanding the true prevalence and epidemiology of the virus.

Conventional and Nested PCR

Conventional PCR assays targeting conserved regions of the EAdV-1 genome, such as the hexon gene, have been widely employed for initial detection and molecular characterization. The hexon gene, which encodes a major capsid protein, contains both conserved and variable regions, making it an ideal target for both broad-spectrum detection and phylogenetic analysis. For instance, a study in the Republic of Korea used a hexon-specific PCR to screen nasal swabs from 359 horses, achieving a detection rate of 1.4% [4]. This approach allowed for the subsequent sequencing of amplicons, revealing a high degree of genetic similarity (98.8–100%) among Korean isolates and with foreign strains from Australia and India, demonstrating the utility of PCR for molecular epidemiology [4]. Nested PCR, which involves two successive rounds of amplification, offers even greater sensitivity and is particularly useful for detecting low viral loads or for screening samples from non-traditional sources. This technique has been instrumental in discovering adenoviruses in novel hosts, such as the first detection of an adenovirus in a vampire bat (Desmodus rotundus) in Brazil, where a nested PCR targeting the DNA polymerase gene was used [5]. While highly sensitive, conventional and nested PCR are primarily qualitative and require post-amplification processing (e.g., gel electrophoresis), which increases the risk of contamination and is less amenable to high-throughput analysis.

Real-Time Quantitative PCR (qPCR)

Real-time quantitative PCR (qPCR) has become the gold standard for the detection and quantification of EAdV-1. This technique allows for the simultaneous amplification and quantification of viral DNA in a closed-tube system, eliminating post-PCR handling and significantly reducing the risk of cross-contamination. The use of fluorescent probes (e.g., TaqMan) or DNA-binding dyes (e.g., SYBR Green) enables the continuous monitoring of amplification, providing a quantitative measure of the viral load in the sample. This quantitative capability is a major advantage, as it can differentiate between high-level active replication and low-level latent or persistent shedding, providing crucial context for clinical interpretation.

The application of qPCR has been central to understanding the role of EAdV-1 in equine respiratory disease. In a comprehensive longitudinal study of 52 Standardbred racehorses, qPCR was used to systematically screen both nasopharyngeal swabs (NS) and tracheal washes (TW) for a panel of respiratory viruses, including EAdV-1 [7]. The study found a monthly incidence of EAdV-1 detection in TW of 1.9%, classifying it as an uncommon finding compared to equine herpesviruses [7]. Crucially, the study demonstrated that detection of viral genome in NS was not associated with any clinical sign, whereas detection in TW was more clinically relevant [7]. This highlights the importance of sample type and the quantitative data provided by qPCR in interpreting the significance of a positive result. The ability to quantify viral load is also critical for research applications, such as assessing the efficacy of antiviral therapies or vaccines.

Nanoscale and Point-of-Care PCR Platforms

The diagnostic landscape is further evolving with the introduction of novel PCR platforms designed for increased throughput and portability. Nanoscale real-time PCR panels, which can simultaneously detect multiple pathogens in a single, small-volume reaction, represent a powerful tool for syndromic surveillance. A study using such a platform to screen fecal samples from apparently healthy horses at a multi-day show detected EAdV-1 DNA, alongside a range of other enteric and respiratory pathogens [8]. This approach provides a comprehensive overview of the pathogen landscape in a population, which is invaluable for understanding co-infections and the role of subclinical carriers in disease transmission. However, the authors caution that the extreme sensitivity of these assays may overestimate the true prevalence of active infection, as they can detect non-viable organisms or low-level shedding that is not clinically significant [8].

Point-of-care (POC) PCR assays represent the next frontier in molecular diagnostics, aiming to bring the speed and accuracy of PCR directly to the patient. While no POC PCR assay is yet commercially available specifically for EAdV-1, the successful development and validation of such assays for other equine pathogens, such as Salmonella spp., demonstrate the feasibility and potential of this technology [12]. These devices are designed to be simple to operate, provide results in under an hour, and require minimal laboratory infrastructure. The development of a POC PCR for EAdV-1 would be a game-changer for outbreak management, allowing for rapid on-farm diagnosis and immediate implementation of quarantine and biosecurity protocols, thereby limiting the spread of infection.

Sample Selection and Diagnostic Context

The choice of clinical specimen is a critical determinant of diagnostic accuracy. For EAdV-1, nasopharyngeal swabs (NS) and tracheal washes (TW) are the most common sample types. However, as highlighted by Doubli-Bounoua et al., the diagnostic yield and clinical interpretation differ significantly between these two sample types [7]. NS are non-invasive and easy to collect, making them ideal for large-scale surveillance. However, detection of EAdV-1 DNA in NS was not associated with clinical signs, suggesting that a positive NS result may reflect superficial contamination, low-level shedding, or the presence of non-replicating virus [7]. In contrast, detection in TW, which samples the lower airways, was more strongly associated with clinical disease, particularly coughing and tracheal mucus accumulation [7]. This suggests that for diagnosing EAdV-1 as a cause of lower respiratory tract disease or inflammatory airway disease (IAD), a TW is the superior sample. The lack of agreement between NS and TW results underscores the need for careful sample selection based on the clinical question being asked.

The interpretation of a positive PCR result must also consider the epidemiological context. EAdV-1 is considered one of the least common respiratory viruses in performing horses, with a prevalence often lower than equine herpesviruses and equine rhinitis viruses [6, 7]. Therefore, a positive result, especially in a horse with clinical signs, is diagnostically significant. However, the virus can also be detected in apparently healthy horses, indicating that subclinical infection and shedding are common [8]. This is particularly relevant in young horses, where respiratory viral infections are frequently observed as they begin training [6]. The detection of EAdV-1 in a horse with respiratory disease does not automatically establish causation, as co-infections with other pathogens are common. The use of multiplex PCR panels that simultaneously test for a range of respiratory viruses (e.g., EHV-1, -2, -4, -5, equine influenza virus, equine rhinitis viruses) is therefore essential for a complete diagnostic workup [7, 8].

Molecular Characterization and Phylogenetic Analysis

Beyond simple detection, molecular tools are indispensable for characterizing EAdV-1 strains and understanding their genetic diversity and evolution. Sequencing of PCR amplicons, particularly from the hexon gene, allows for phylogenetic analysis and comparison of isolates from different geographic regions. This has revealed that EAdV-1 strains are relatively conserved globally, with Korean isolates sharing 98.8–100% nucleotide identity with strains from Australia and India [4]. However, the same study also identified two isolates that were phylogenetically distinct, suggesting the presence of multiple circulating lineages [4]. This genetic diversity has implications for diagnostic assay design, as primers and probes must be designed to detect all circulating variants. Furthermore, phylogenetic tracking is a powerful tool for outbreak investigations, allowing researchers to trace the source of an infection and understand transmission pathways.

Diagnostic Challenges and Future Directions

Despite the power of molecular diagnostics, several challenges remain. The extreme sensitivity of PCR means that strict protocols must be followed to prevent contamination. The detection of non-viable virus or nucleic acid fragments can lead to false-positive results, particularly in environmental samples or in horses that have recently recovered from infection. The lack of standardization between different PCR assays and laboratories can also make it difficult to compare results across studies. Furthermore, the cost and technical expertise required for qPCR can be a barrier to its widespread use in some settings.

Future directions for EAdV-1 diagnostics will likely focus on the development of more rapid, portable, and multiplexed platforms. The integration of CRISPR-based diagnostics, which offer isothermal amplification and detection with minimal equipment, holds great promise for true point-of-care applications. Additionally, the use of metagenomic next-generation sequencing (mNGS) could provide an unbiased approach to pathogen detection, identifying not only EAdV-1 but also unexpected or novel pathogens in a single assay. This would be particularly valuable for investigating complex respiratory disease outbreaks where conventional testing has failed to identify a causative agent. As our understanding of the equine respiratory virome expands, the diagnostic approach will continue to evolve, moving from targeted detection of a few known pathogens to a more holistic, systems-based analysis of the entire microbial community.

Prevention, Control, and Biosecurity Measures for Equine Adenovirus 1

The prevention and control of Equine Adenovirus 1 (EAdV-1) infection presents a unique challenge within equine medicine, primarily because the virus is endemic in horse populations worldwide, yet its clinical significance is often overshadowed by more overtly pathogenic respiratory viruses such as Equine Herpesvirus-1 (EHV-1) and Equine Influenza Virus (EIV). The strategic framework for managing EAdV-1 must be built upon a foundation of robust biosecurity protocols, targeted vaccination strategies where applicable, and a deep understanding of the epidemiological drivers of transmission, particularly in high-risk populations such as immunocompromised foals and intensively managed athletic horses. The World Organisation for Animal Health (WOAH) and the Centers for Disease Control and Prevention (CDC) provide overarching guidelines for managing respiratory pathogens in livestock, but specific recommendations for EAdV-1 must be extrapolated from the broader principles of adenovirus control and the limited, yet critical, equine-specific research available.

Understanding the Epidemiological Context for Control

Effective control measures are predicated on a thorough understanding of how EAdV-1 circulates and persists within equine populations. The virus is primarily transmitted via the respiratory route through direct contact with infected horses or indirect contact via contaminated fomites, including shared water buckets, feed troughs, grooming equipment, and human hands. The detection of EAdV-1 in nasal swabs from apparently healthy horses, as demonstrated in a Korean study where only one of five PCR-positive horses showed clinical signs [4], underscores the critical role of subclinical shedders in maintaining viral circulation. This phenomenon is not unique to EAdV-1; it is a hallmark of many respiratory viruses, including equine herpesviruses, where latent infections can reactivate under stress [6]. The presence of EAdV-1 in healthy horses at multi-day events [8] further confirms that the virus can be introduced into congregate settings by asymptomatic carriers, making pre-emptive biosecurity measures more important than reactive ones.

The epidemiology of EAdV-1 is also shaped by host factors, particularly age and immune status. Experimental infections have clearly demonstrated that neonatal foals, especially those deprived of colostrum, are far more susceptible to severe, life-threatening pneumonia than older foals or adults [3, 2]. This age-related susceptibility is a direct consequence of the immature adaptive immune system in neonates. The critical role of passive transfer of maternal antibodies is highlighted by the observation that colostrum-fed foals developed less severe disease than colostrum-deprived foals following experimental challenge [3]. Furthermore, the devastating impact of EAdV-1 in Arabian foals with combined immunodeficiency (CID), characterized by severe, persistent lymphopenia [3], illustrates that any condition compromising cell-mediated immunity dramatically increases the risk of fatal adenoviral disease. Therefore, control strategies must be stratified, with the most stringent measures reserved for breeding farms with neonatal foals, particularly those with known immunodeficiencies, and for populations of young horses entering training, where the stress of transport and novel environments can increase susceptibility to viral infections [6].

Core Biosecurity Protocols for EAdV-1 Management

Biosecurity for EAdV-1 must be integrated into a comprehensive infectious disease control program that targets all respiratory pathogens. The fundamental principles of isolation, sanitation, and traffic control are paramount. Any horse presenting with acute respiratory signs, fever, nasal discharge, cough, or conjunctivitis, should be immediately isolated from the general population. While EAdV-1 is often a mild pathogen, the clinical signs are indistinguishable from those caused by EHV-1, EIV, or Streptococcus equi subsp. equi (strangles), all of which have far greater consequences for individual and herd health. A definitive diagnosis via PCR on nasopharyngeal swabs [4, 7] is essential to guide specific management decisions and to rule out reportable or more dangerous pathogens. The isolation period should be maintained until clinical signs have resolved and, ideally, until a negative PCR result is obtained, although the duration of viral shedding in naturally infected horses is not precisely defined for EAdV-1.

Environmental sanitation is a critical, yet often overlooked, component of control. Adenoviruses are non-enveloped viruses, which confers a significant advantage in terms of environmental stability. Unlike enveloped viruses such as EHV-1 and EIV, which are readily inactivated by lipid solvents and many common disinfectants, non-enveloped viruses like EAdV-1 are resistant to a wider range of environmental conditions and chemical agents. This resistance means that standard quaternary ammonium compounds may be insufficient. Effective disinfection against adenoviruses requires the use of agents with proven virucidal activity against non-enveloped viruses, such as accelerated hydrogen peroxide, sodium hypochlorite (bleach) at appropriate dilutions (e.g., 1:10 for contaminated surfaces), or peracetic acid. All surfaces in contact with an infected horse, stall walls, floors, feed and water buckets, and grooming tools, must be thoroughly cleaned of organic matter before disinfection, as organic material can neutralize disinfectant activity. The use of separate equipment for isolated horses is non-negotiable.

Traffic control is the third pillar of biosecurity. This involves minimizing the movement of people, horses, and equipment between different groups of horses on a farm. A logical flow should be established, moving from young, susceptible animals to older, more resistant ones, and from healthy populations to isolated or sick ones. Hand hygiene is a simple but profoundly effective measure. Personnel should wash their hands or use alcohol-based hand sanitizers before and after handling any horse, and dedicated footwear or footbaths with appropriate disinfectant should be used when entering and exiting isolation areas. For equine events, the detection of EAdV-1 in healthy horses [8] reinforces the need for general biosecurity practices, such as avoiding shared water sources and nose-to-nose contact between horses from different premises. The stress of transportation itself is a known risk factor for respiratory viral infections [6], so minimizing travel time and ensuring adequate ventilation in horse trailers are important preventive measures.

Vaccination Strategies and Immunological Considerations

Currently, there is no commercially available vaccine specifically licensed for EAdV-1 in horses. This represents a significant gap in our preventive armamentarium, particularly for high-risk populations. The development of an effective vaccine is complicated by several factors. First, the disease is most severe in very young foals with immature immune systems, making it difficult to induce a protective response before natural exposure occurs. Second, the virus is ubiquitous, and most adult horses have pre-existing immunity from natural infection, which may blunt the response to a vaccine. However, the experimental evidence provides a strong proof-of-concept for vaccination. A landmark study using specific-pathogen-free foals demonstrated that two subcutaneous immunizing injections of an inactivated EAdV vaccine with adjuvant conferred complete protection against clinical disease and significantly reduced pulmonary pathology following a virulent challenge [2]. This study unequivocally shows that a protective immune response can be generated.

Further evidence for the feasibility of vaccination comes from studies on the immune response to EAdV-1. An inactivated vaccine was shown to boost virus-neutralizing (VN) antibody titers in adult horses that already had pre-existing immunity, and importantly, it also induced a robust cell-mediated immune response, as measured by in vitro lymphocyte blastogenesis [9]. This is a critical finding, as cell-mediated immunity is essential for clearing intracellular viral infections, including adenoviruses. The induction of both humoral and cellular arms of the immune system is the hallmark of an effective vaccine. The experimental vaccine used in these studies was an inactivated whole-virus preparation with adjuvant [2, 9]. This approach is safe and can be effective, but it may require multiple doses to induce a durable immune response.

Given the lack of a licensed vaccine, the focus must be on optimizing passive immunity through colostrum management. Ensuring that neonatal foals receive adequate, high-quality colostrum within the first 12-24 hours of life is the single most important preventive measure against severe EAdV-1 disease. The experimental data clearly show that colostrum-deprived foals are at extreme risk [3, 2]. On farms with a history of EAdV-1 problems or where Arabian foals are bred, measuring serum IgG levels in foals is a prudent practice. For foals with failure of passive transfer, administration of hyperimmune plasma from a donor with high EAdV-1 antibody titers could be considered, although this is not a routine practice and its efficacy is not well-documented in controlled trials. The development of a maternal vaccine that could boost colostral antibody levels against EAdV-1 would be a highly valuable tool, but this remains a research goal rather than a current reality.

Management of High-Risk Populations: Immunodeficient Foals and Athletic Horses

The management of EAdV-1 must be tailored to the specific risk profile of the population. For breeding farms, the primary goal is to protect neonatal foals. This begins with maintaining a clean, low-stress environment for mares and foals. Foaling stalls should be thoroughly cleaned and disinfected between uses. Minimizing the introduction of new horses onto the farm, especially during foaling season, is critical. Any new arrival should be quarantined for a minimum of 2-3 weeks and monitored for signs of respiratory disease. The most vulnerable animals are Arabian foals, which have a high incidence of CID. Any foal that fails to thrive, develops recurrent infections, or shows persistent lymphopenia should be aggressively investigated for immunodeficiency. If CID is confirmed, the foal should be maintained in strict isolation, and the prognosis is grave, as they are susceptible to a wide range of opportunistic infections, including fatal EAdV-1 pneumonia [3].

For performance horses, the primary concern is the impact of EAdV-1 on respiratory health and athletic performance. While EAdV-1 is often subclinical, it can contribute to inflammatory airway disease (IAD), a condition that impairs gas exchange and reduces exercise tolerance [7]. The management of EAdV-1 in this context is part of a broader strategy to minimize respiratory disease. This includes optimizing stable ventilation to reduce the concentration of airborne pathogens and dust, implementing a vaccination program against EIV and EHV-1 (which may reduce overall respiratory disease burden), and managing stress. The stress of training, transportation, and competition is a well-recognized trigger for respiratory viral infections [6]. Therefore, providing adequate rest periods, ensuring proper nutrition, and avoiding over-training are all important preventive measures. When an outbreak of respiratory disease occurs in a training yard, rapid diagnosis using PCR panels that include EAdV-1 [7, 8] is essential to understand the etiology and implement targeted control measures. Infected horses should be rested from training until clinical signs have fully resolved, as exercising with a respiratory infection can exacerbate lung damage and prolong recovery.

Integrating EAdV-1 Control into a One Health Framework

While EAdV-1 is not a zoonotic pathogen, the principles of its control are deeply embedded in the One Health concept, which recognizes the interconnectedness of human, animal, and environmental health. The use of antimicrobials in horses is a significant concern due to the emergence of antimicrobial resistance (AMR) [13, 14]. EAdV-1, being a virus, does not respond to antibiotics. However, secondary bacterial infections are a common complication of viral respiratory disease, particularly in foals with viral pneumonia. Judicious use of antimicrobials, guided by bacterial culture and sensitivity testing, is essential to preserve their efficacy for bacterial infections. The widespread empirical use of Category B antimicrobials (e.g., fluoroquinolones, third-generation cephalosporins) in equine practice [14] is a major driver of AMR, and this practice must be curtailed. Preventing viral infections like EAdV-1 through good biosecurity and management directly reduces the need for antimicrobial therapy, thereby contributing to the global fight against AMR.

Furthermore, the environmental persistence of EAdV-1 and other equine pathogens necessitates responsible waste management. The composting of equine mortality, including horses euthanized with sodium pentobarbital, is an emerging practice that must be carefully managed to prevent environmental contamination with pathogens and chemical residues [15]. While the focus of that study was on barbiturate degradation, the principles of proper carcass disposal are equally relevant to preventing the spread of infectious agents. Composting, if done correctly, can generate sufficient heat to inactivate many viruses and bacteria, but its efficacy against non-enveloped viruses like EAdV-1 requires further investigation. The development of evidence-based guidelines for the disposal of infected bedding and other contaminated materials is an important aspect of comprehensive biosecurity planning. In conclusion, the control of EAdV-1 is not an isolated endeavor but an integral part of a holistic health management program that prioritizes prevention, minimizes stress, optimizes immunity, and promotes responsible antimicrobial use, all within a framework that acknowledges the links between animal health, human health, and the environment.

References

[1] Studdert MJ, Blackney M. Isolation of an adenovirus antigenically distinct from equine adenovirus type 1 from diarrheic foal feces.. American Journal of Veterinary Research. 1982. DOI: https://doi.org/10.2460/ajvr.1982.43.03.543

[2] Lj G, Studdert M, Sullivan ND. Pathogenicity and immunologic studies of equine adenovirus in specific-pathogen-free foals.. American Journal of Veterinary Research. 1978. DOI: https://doi.org/10.2460/ajvr.1978.39.10.1636

[3] Ae M, Jj E, Ce W, Jl A, Lj R, Tl C. Experimental transmission of equine adenovirus in Arabian and non-Arabian foals.. American Journal of Veterinary Research. 1974. DOI: https://doi.org/10.2460/ajvr.1974.35.08.1015

[4] Lee S, Choi J, Yoon J, Jung J, Park J, Park J, et al.. Molecular Detection of Equine Adenovirus 1 in Nasal Swabs from Horses in the Republic of Korea. Veterinary Sciences. 2022. DOI: https://doi.org/10.3390/vetsci9040187

[5] Lima FES, Cibulski S, Elesbao F, Junior PC, Batista HBCR, Roehe P, et al.. First detection of adenovirus in the vampire bat (Desmodus rotundus) in Brazil. Virus genes. 2013. DOI: https://doi.org/10.1007/s11262-013-0947-6

[6] Frippiat T, Wollenberg Lvd, Erck-Westergren Ev, Maanen Kv, Votion D. Respiratory viruses affecting health and performance in equine athletes.. Virology. 2024. DOI: https://doi.org/10.1016/j.virol.2024.110372

[7] Doubli-Bounoua N, Richard E, Léon A, Pitel P, Pronost S, Fortier G. Multiple molecular detection of respiratory viruses and associated signs of airway inflammation in racehorses. Virology Journal. 2016. DOI: https://doi.org/10.1186/s12985-016-0657-5

[8] Stout AE, Hofmar-Glennon HG, André N, Goodman L, Anderson RR, Mitchell PK, et al.. Infectious disease surveillance of apparently healthy horses at a multi-day show using a novel nanoscale real-time PCR panel. Journal of Veterinary Diagnostic Investigation. 2020. DOI: https://doi.org/10.1177/1040638720972096

[9] Tm C, Mj S. In vitro blastogenesis of equine lymphocytes by inactivated equine adenovirus type 1 antigen.. American Journal of Veterinary Research. 1982. DOI: https://doi.org/10.2460/ajvr.1982.43.11.1922

[10] Khusro A, Aarti C, Rivas-Cáceres R, Barbabosa‐Pliego A. Equine Herpesvirus-I Infection in Horses: Recent Updates on its Pathogenicity, Vaccination, and Preventive Management Strategies.. Journal of Equine Veterinary Science. 2020. DOI: https://doi.org/10.1016/j.jevs.2020.102923

[11] Couroucé A, Normand C, Tessier C, Pomares R, Thevenot J, Marcillaud-Pitel C, et al.. Equine herpesvirus-1 outbreak during a show-jumping competition: a clinical and epidemiological study.. Journal of Equine Veterinary Science. 2023. DOI: https://doi.org/10.1016/j.jevs.2023.104869

[12] Pusterla N, Lawton K, Barnum S, Vitomirov A, Anaya S, Naranatt P, et al.. Detection of Salmonella spp. in pooled environmental samples from an equine veterinary hospital using a novel point-of-care PCR assay.. Journal of Equine Veterinary Science. 2025. DOI: https://doi.org/10.1016/j.jevs.2025.105376

[13] Jacobsen ABJE, Damborg P, Hopster‐Iversen C. Usage of antimicrobials in equine veterinary practice in Denmark - A case-based survey.. Journal of Equine Veterinary Science. 2023. DOI: https://doi.org/10.1016/j.jevs.2023.104267

[14] Allen SE, Verheyen K, O'Neill D, Brodbelt D. Use of antimicrobials licensed for systemic administration in UK equine practice.. Equine Veterinary Journal. 2022. DOI: https://doi.org/10.1111/evj.13878

[15] Lochner H, Hutchinson M, Wilson ML, Bianco AW, Johnston L, Prigge J, et al.. Characteristics and sodium pentobarbital concentrations of equine mortality compost piles in the Upper Midwest.. Journal of Equine Veterinary Science. 2022. DOI: https://doi.org/10.1016/j.jevs.2022.104000

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.